Current Report Filing (8-k)
February 12 2018 - 8:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): February 12, 2018
CATALYST PHARMACEUTICALS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
|
|
|
|
|
Delaware
|
|
001-33057
|
|
76-0837053
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
355 Alhambra Circle
Suite 1250
Coral Gables,
Florida
|
|
33134
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (305)
420-3200
Not Applicable
Former Name or Former address, if changed since last report
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
Chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging Growth Company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On February 12, 2018, the Company announced the results of its recent Type C meeting
with the U.S. Food and Drug Administration (FDA). Prior to the meeting, the Company had provided the FDA with its preliminary data package for the proposed NDA resubmission for Firdapse
®
,
including clinical,
non-clinical,
regulatory and abuse liability elements, along with the recently reported positive
top-line
results from a second, confirmatory Phase 3
clinical trial of Firdapse
®
for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and the recently completed
FDA-required
abuse
liability studies demonstrating that Firdapse
®
does not have abuse potential. The minutes of the meeting received from the FDA reflect the FDAs advice to the Company that its proposed
filing package will be sufficient for resubmission of an NDA for Firdapse
®
, and the Company currently anticipates resubmitting its NDA for
Firdapse
®
for LEMS to the FDA by the end of the first quarter of 2018.
The Company also
announced that it expects to report
top-line
results from its Phase 3 double-blind placebo-controlled study evaluating Firdapse
®
for the treatment of
congenital myasthenic syndromes (CMS) in the second half of this year, and that it is evaluating its options for the most appropriate and efficient path forward to include CMS in any approved labeling of Firdapse
®
.
The Companys press release is attached to this Current Report on
Form 8-K
as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
Catalyst Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Alicia Grande
|
|
|
Alicia Grande
|
|
|
Vice President, Treasurer and CFO
|
Dated: February 12, 2018
3
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024